immunotherapy

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to…

5 days ago

IMUNON Files IND Application to Begin Human Testing of IMNN-101

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided…

5 days ago

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

International Society for Cell & Gene Therapy (ISCT) Names Dr. Lowdell with the Career Achievement Award in Cell and Gene Therapy…

5 days ago

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE…

5 days ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW…

5 days ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…

5 days ago

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…

6 days ago

Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines

KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that…

6 days ago

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities…

6 days ago

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted…

6 days ago